4.7 Article

A circadian clock is essential for homeostasis of group 3 innate lymphoid cells in the gut

期刊

SCIENCE IMMUNOLOGY
卷 4, 期 40, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciimmunol.aax1215

关键词

-

资金

  1. NIH [R01AI143842, R01AI123368, R01AI145989, U01AI095608]
  2. NIAID Mucosal Immunology Studies Team (MIST)
  3. Crohn's and Colitis Foundation of America
  4. Searle Scholars Program
  5. American Asthma Foundation Scholar Award
  6. Center for Advanced Digestive Care (CADC)
  7. Wade F.B. Thompson/Cancer Research Institute CLIP Investigator grant
  8. Meyer Cancer Center Collaborative Research Initiative
  9. Jill Roberts Institute (JRI) for Research in IBD
  10. Crohn's and Colitis Foundation [608975, 519428]
  11. Burroughs Wellcome Fund

向作者/读者索取更多资源

Group 3 innate lymphoid cells (ILC3s) critically orchestrate host-microbe interactions in the healthy mammalian intestine and become substantially impaired in the context of inflammatory bowel disease (IBD). However, the molecular pathways controlling the homeostasis of ILC3s remain incompletely defined. Here, we identify that intestinal ILC3s are highly enriched in expression of genes involved in the circadian clock and exhibit diurnal oscillations of these pathways in response to light cues. Classical ILC3 effector functions also exhibited diurnal oscillations, and lineage-specific deletion of BMAL1, a master regulator of the circadian clock, resulted in markedly reduced ILC3s selectively in the intestine. BMAL1-deficient ILC3s exhibit impaired expression of Nr1d1 and Per3, hyperactivation of ROR gamma t-dependent target genes, and elevated proapoptotic pathways. Depletion of the microbiota with antibiotics partially reduced the hyperactivation of BMAL1-deficient ILC3s and restored cellular homeostasis in the intestine. Last, ILC3s isolated from the inflamed intestine of patients with IBD exhibit substantial alterations in expression of several circadian-related genes. Our results collectively define that circadian regulation is essential for the homeostasis of ILC3s in the presence of a complex intestinal microbiota and that this pathway is disrupted in the context of IBD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Dermatology

Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients

Suiting Ao, Xuemei Gao, Jipang Zhan, Lu Ai, Minyi Li, Huilin Su, Xuhua Tang, Coco Chu, Jiande Han, Fang Wang

Summary: The combination of TNF-alpha inhibition and steroids showed better outcomes in treating SJS/TEN compared to steroid monotherapy, significantly shortening the duration of acute phase, hospitalization stay, and skin reepithelialization time. IL-15 was positively correlated with skin reepithelialization time in both groups, while IL-6 served as an additional marker for disease progression in the combination therapy group.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Article Immunology

Group 3 innate lymphoid cells produce the growth factor HB-EGF to protect the intestine from TNF-mediated inflammation

Lei Zhou, Wenqing Zhou, Ann M. Joseph, Coco Chu, Gregory G. Putzel, Beibei Fang, Fei Teng, Mengze Lyu, Hiroshi Yano, Katrin I. Andreasson, Eisuke Mekada, Gerard Eberl, Gregory F. Sonnenberg

Summary: Group 3 innate lymphoid cells (ILC3s) protect the intestine from TNF-induced cell death by producing heparin-binding epidermal growth factor-like growth factor (HB-EGF), thereby playing a crucial role in inflammatory bowel disease (IBD).

NATURE IMMUNOLOGY (2022)

Article Oncology

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Manish A. Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C. Tebbutt, Jean-Phillippe Metges, Kei Muro, Keun-Wook Lee, Lin Shen, Sergei Tjulandin, John L. Hays, Naureen Starling, Rui-Hua Xu, Keren Sturtz, Marilyn Fontaine, Cindy Oh, Emily M. Brooks, Bo Xu, Wei Li, Chiang J. Li, Laura Borodyansky, Eric Van Cutsem

Summary: Adding napabucasin to paclitaxel did not improve survival in patients with second-line advanced gastric or gastroesophageal junction adenocarcinoma. The safety profile of napabucasin was driven by manageable gastrointestinal events, with grade >= 3 diarrhea occurring at a higher frequency with napabucasin plus paclitaxel versus placebo plus paclitaxel.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

Manish A. Shah, Anghel Adrian Udrea, Igor Bondarenko, Was Mansoor, Raquel Guardeno Sanchez, Tomasz Sarosiek, Silvia Bozzarelli, Michael Schenker, Carlos Gomez-Martin, Carys Morgan, Mustafa oezgueroglu, Joanna Pikiel, Haralabos P. Kalofonos, Elzbieta Wojcik, Tomas Buchler, Daniel Swinson, Irfan Cicin, Mano Joseph, Ihor Vynnychenko, Alexander Valerievich Luft, Peter C. Enzinger, Tomas Salek, Christos Papandreou, Christophe Tournigand, Evaristo Maiello, Ran Wei, David Ferry, Ling Gao, Joana M. Oliveira, Jaffer A. Ajani

Summary: Ramucirumab at a dosage of 8 mg/kg every 2 weeks is a standard treatment option for second-line advanced/metastatic gastric/gastroesophageal junction adenocarcinoma, either as monotherapy or in combination with paclitaxel. Different dosing regimens were explored in these studies, but there was no dose/exposure-response relationship supporting the use of the standard dose of ramucirumab.

CANCERS (2022)

Article Multidisciplinary Sciences

ZBTB46 defines and regulates ILC3s that protect the intestine

Wenqing Zhou, Lei Zhou, Jordan Zhou, Coco Chu, Chao Zhang, Robbyn E. Sockolow, Gerard Eberl, Gregory F. Sonnenberg

Summary: This study defines ROR gamma t(+) immune cells in the intestine at single-cell resolution and identifies a subset of ILC3s that expresses ZBTB46, a transcription factor shared with conventional dendritic cells. ZBTB46 restrains the inflammatory properties of ILC3s and plays a non-redundant role in orchestrating intestinal health.

NATURE (2022)

Article Oncology

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial

Josep Tabernero, Paulo M. Hoff, Lin Shen, Atsushi Ohtsu, Manish A. Shah, Asna Siddiqui, Sarah Heeson, Astrid Kiermaier, Harrison Macharia, Eleonora Restuccia, Yoon-Koo Kang

Summary: This study aimed to evaluate the long-term efficacy and safety of pertuzumab plus trastuzumab and chemotherapy in previously untreated HER2-positive metastatic gastric or gastroesophageal junction cancer. The results showed increased overall survival and progression-free survival, higher objective response rate, and comparable safety in the pertuzumab arm.

GASTRIC CANCER (2023)

Article Oncology

Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study

Manish A. Shah, Takayuki Yoshino, Niall C. Tebbutt, Axel Grothey, Josep Tabernero, Rui-Hua Xu, Andres Cervantes, Sang Cheul Oh, Kensei Yamaguchi, Marwan Fakih, Alfredo Falcone, Christina Wu, Vi K. Chiu, Jiri Tomasek, Johanna Bendell, Marilyn Fontaine, Matthew Hitron, Bo Xu, Julien Taieb, Eric Van Cutsem

Summary: In this study, patients with colorectal cancer were divided into two groups, one receiving combination therapy of napabucasin and FOLFIRI, and the other receiving FOLFIRI alone. The results showed that the addition of napabucasin to FOLFIRI did not significantly improve overall survival compared to the control group.

CLINICAL COLORECTAL CANCER (2023)

Article Oncology

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline

Manish A. Shah, Erin B. Kennedy, Ashley E. Alarcon-Rozas, Thierry Alcindor, Angela N. Bartley, Aubrey Belk Malowany, Nishin A. Bhadkamkar, Dana C. Deighton, Yelena Janjigian, Asha Karippot, Uqba Khan, Daniel A. King, Kelsey Klute, Jill Lacy, James J. Lee, Rutika Mehta, Sarbajit Mukherjee, Arun Nagarajan, Haeseong Park, Anwaar Saeed, Thomas J. Semrad, Kohei Shitara, Elizabeth Smyth, Nataliya Uboha, Melani Vincelli, Zev Wainberg, Lakshmi Rajdev

Summary: The purpose of this study is to develop recommendations for targeted therapies in advanced gastroesophageal cancer. A systematic review was conducted, and 18 randomized controlled trials were included. The recommendations include first-line therapy with nivolumab and chemotherapy for HER2-negative patients with gastric adenocarcinoma and PD-L1 CPS >= 5, and pembrolizumab and chemotherapy for HER2-negative patients with esophageal or gastroesophageal junction AC and PD-L1 CPS >= 10. Clinical trials are recommended as targeted treatment options for gastroesophageal cancer are expected to evolve.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Multidisciplinary Sciences

Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers

Walid K. Chatila, Henry Walch, Jaclyn F. Hechtman, Sydney M. Moyer, Valeria Sgambati, David M. Faleck, Amitabh Srivastava, Laura Tang, Jamal Benhamida, Dorina Ismailgeci, Carl Campos, Fan Wu, Qing Chang, Efsevia Vakiani, Elisa de Stanchina, Martin R. Weiser, Maria Widmar, Rhonda K. Yantiss, Manish A. Shah, Adam J. Bass, Zsofia K. Stadler, Lior H. Katz, Ingo K. Mellinghoff, Nilay S. Sethi, Nikolaus Schultz, Karuna Ganesh, David Kelsen, Rona Yaeger

Summary: Inflammation is recognized as a contributing factor to cancer development, particularly in the gastrointestinal tract. In this study, the clinical features, genomic landscape, and germline alterations of colitis-associated cancers were defined. TP53 alterations were a common event in colitis-associated cancers, occurring in half of dysplasia, while Wnt pathway alterations were infrequent. The sequencing results from multiple dysplasia/cancer lesions suggest that these lesions largely occur as genetically independent events with lineage plasticity away from Wnt activation.

NATURE COMMUNICATIONS (2023)

Article Oncology

Long COVID in Cancer A Matched Cohort Study of 1-year Mortality and Long COVID Prevalence Among Patients With Cancer Who Survived an Initial Severe SARS-CoV-2 Infection

Olivia Fankuchen, Jennifer Lau, Mangala Rajan, Brandon Swed, Peter Martin, Manuel Hidalgo, Samuel Yamshon, Laura Pinheiro, Manish A. Shah

Summary: This study examined the long-term effects of COVID-19 infection in cancer patients and found that cancer patients had higher mortality rates after hospital discharge. Additionally, approximately one-third of all patients experienced long COVID symptoms.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2023)

Article Medicine, General & Internal

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro- oesophageal junction adenocarcinoma (SPOTLIGHT) : a multicentre, randomised, double-blind, phase 3 trial

Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Manish A. Shah, Eric Van Cutsem, Rui-Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani

Summary: Zolbetuximab in combination with mFOLFOX6 significantly prolongs progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, with good safety profile.

LANCET (2023)

Review Oncology

Improving outcomes in patients with oesophageal cancer

Manish A. Shah, Nasser Altorki, Pretish Patel, Sebron Harrison, Adam Bass, Julian A. Abrams

Summary: Oesophageal cancer is a common malignancy with significant morbidity and mortality. Advances in disease understanding, screening, monitoring technologies, surgical techniques, radiotherapy, and systemic therapy have improved patient outcomes. The development of minimally invasive diagnostic technologies based on cancer-specific genomic or epigenetic alterations has the potential to enhance screening. Less invasive surgical techniques and immune-checkpoint inhibitors also hold promise in improving treatment. This review discusses these advances and highlights the ongoing transformation in oesophageal cancer management.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Editorial Material Oncology

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Q and A

Lakshmi Rajdev, Erin B. Kennedy, Manish A. Shah

JCO ONCOLOGY PRACTICE (2023)

Article Biochemistry & Molecular Biology

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, Yung-Jue Bang, Peter Enzinger, David Ilson, Florian Lordick, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, Hwoei Fen Soo Hoo, Haci Mehmet Turk, Mok Oh, Jung Wook Park, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Rui-Hua Xu

Summary: The GLOW trial demonstrated that zolbetuximab, a monoclonal antibody targeting CLDN18.2, combined with CAPOX, significantly improved progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

NATURE MEDICINE (2023)

Article Oncology

Circulating IgA Antibodies Against Fusobacterium nucleatum Amyloid Adhesin FadA are a Potential Biomarker for Colorectal Neoplasia

Jung Eun Baik, Li Li, Manish A. Shah, Daniel E. Freedberg, Zhezhen Jin, Timothy C. Wang, Yiping W. Han

Summary: Fusobacterium nucleatum (Fn) is a common gram-negative anaerobic bacterium that promotes colorectal cancer development through the secretion of FadAc. This study found that circulating levels of anti-FadAc IgA were significantly increased in patients with colorectal cancer, particularly in those with proximal tumors. Therefore, anti-FadAc IgA may serve as a serological biomarker for early detection of colorectal cancer.

CANCER RESEARCH COMMUNICATIONS (2022)

暂无数据